INDIANAPOLIS, Feb. 6 /PRNewswire/ -- Roche announced today that people with diabetes will see a significant price reduction on the price of both the ACCU-CHEK(R) Aviva and ACCU-CHEK(R) Compact Plus Meter Care Kits, effective immediately.
"We are pleased to be able to provide our customers with diabetes two of the leading blood glucose meters on the market at a significantly reduced price," said Roche Vice President of Marketing Dan Kane. "In today's economic environment, we know it's becoming considerably harder for people to make ends meet. Yet it is so important to continue to effectively manage health issues like diabetes by monitoring blood glucose."
Effective immediately, customers will see an everyday shelf price of about $20 for each of the two ACCU-CHEK(R) blood glucose meter care kits wherever ACCU-CHEK(R) products are sold.
Kane added, "We're all feeling the pinch of these current economic times, but there are just some things we shouldn't skimp on-our health is one of those things. By offering people with diabetes new and innovative technology at affordable prices, we hope to encourage them to begin and continue to effectively manage their disease and achieve positive outcomes."
About Roche Diabetes Care
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management-from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems.
For more information, please visit www.accu-chek.com.
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's largest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Roche Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in vitro diagnostics and drugs for cancer and transplantation as well as a market leader in virology. It is also active in other major therapeutic areas, such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners-including majority ownership interests in Genentech and Chugai-and has invested over 8 billion Swiss francs in R&D in 2007. Worldwide, Roche employs about 79,000 people. Additional information is available on the Internet at www.roche-diagnostics.us.
For further information, please contact: Julie Vincent Public Relations Manager ACCU-CHEK(R) Brand email@example.com 317-521-1910
Copyright©2009 PR Newswire.
All rights reserved